• Explore /
  • Poster
  • / Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

Abstract Poster

Authors

Frederick Locke

Frederick Lundry Locke

Moffitt Cancer Center, Tampa, FL

Frederick Lundry Locke , Armin Ghobadi , Lazaros J. Lekakis , David Bernard Miklos , Caron A. Jacobson , Eric D. Jacobsen , Ira Braunschweig , Olalekan O. Oluwole , Tanya Siddiqi , Yi Lin , Patrick Michael Reagan , Umar Farooq , Abhinav Deol , Adrian Bot , John M. Rossi , Yizhou Jiang , Allen Xue , William Y. Go , Sattva Swarup Neelapu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Cellular Immunotherapy

Clinical Trial Registration Number

NCT02348216

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3039)

DOI

10.1200/JCO.2018.36.15_suppl.3039

Abstract #

3039

Poster Bd #

253

Abstract Disclosures

Similar Posters

First Author: Paolo Strati

First Author: Sattva Swarup Neelapu

Poster

2020 ASCO Virtual Scientific Program

Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.

Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.

First Author: Frederick Lundry Locke

First Author: Sattva Swarup Neelapu